Inovio Pharma (INO) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results
March 16, 2015 6:30 AM EDTPLYMOUTH MEETING, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq: INO) today reported financial results for the fourth quarter and year ended December 31, 2014.
Total revenue was $2.5 million and $10.5 million for the quarter and year ended December 31, 2014, as compared to $1.7 million and $13.5 million for the same periods in 2013.
Total operating expenses for the quarter and year ended December 31, 2014, were $13.5 million and $50.0 million as compared to $9.7 million and $33.0 million for the same periods in 2013.
The net loss attributable to common stockholders for the quarter and year ended December 31, 2014, was $7.4 million, or $0.12 per... More
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results
March 16, 2015 6:30 AM EDTPLYMOUTH MEETING, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq: INO) today reported financial results for the fourth quarter and year ended December 31, 2014.
Total revenue was $2.5 million and $10.5 million for the quarter and year ended December 31, 2014, as compared to $1.7 million and $13.5 million for the same periods in 2013.
Total operating expenses for the quarter and year ended December 31, 2014, were $13.5 million and $50.0 million as compared to $9.7 million and $33.0 million for the same periods in 2013.
The net loss attributable to common stockholders for the quarter and year ended December 31, 2014, was $7.4 million, or $0.12 per... More
